At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).

Adverum Biotechnologies, Inc. ADVM announced that it has completed the investigational new drug (“IND”) amendment with the FDA to begin a mid-stage study on its gene therapy candidate, ADVM-022, for ...

Adverum Biotechnologies, Inc. ADVM announced that it has received feedback from the FDA on its investigational new drug (IND) application for initiating a phase II study to evaluate its eye disorder ...

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter. Even ...

Adverum will sell the shares at a price per share of $1.20, representing a premium of approximately 20% to its stock’s 30-day volume-weighted average price, and the financing is expected to close on ...

Adverum Biotechnologies Inc (NASDAQ:ADVM) released data from its ongoing LUNA Phase 2 trial for Ixo-vec in patients with wet age-related macular degeneration (AMD). The 26-week interim analysis was ...

Adverum Biotechnologies Inc. Annual cash flow by MarketWatch. View ADVM net cash flow, operating cash flow, operating expenses and cash dividends.

The firm just released early stage data for its wet AMD gene therapy treatment The shares of Adverum Biotechnologies Inc (NASDAQ:ADVM) are taking a serious nosedive today, down 32.8% at $8.07, after ...

Beyond, ADVM-022, we are focused on developing a pipeline of novel gene therapies. Our industry-leading AAV platform provides us with a number of compelling options for expansion and we look forward ...